Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
23andMe Turns To Drug Discovery
by Rick Mullin
March 23, 2015
| A version of this story appeared in
Volume 93, Issue 12
23andMe, a pioneer in providing personal DNA screening, now plans to pursue drug discovery. The effort will be run by Richard Scheller, the former head of research and early development at Genentech. 23andMe has made significant changes to its business plan following a 2013 FDA determination that its Personal Genome Service is a diagnostic requiring agency approval. Over the past two years, the company has pursued drug discovery partnerships, including one with Genentech to analyze genomics data for Parkinson’s disease.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter